It’s a bloody business, but Mavely (founder and CEO, Axio Biosolutions) is on the good side of it. He sells proprietary emergency blood clotting pads to military and paramilitary forces, and last year expanded to West Asia and Britain. In 2016, Axio set up a factory in Ahmedabad, with an initial capacity of 250,000 units that can be expanded up to 500,000. Mavely says the company has so far sold 1.3 lakh units of its easy-to-peel haemostatic (bleeding reduction) pads. The company is now seeking a U.S. Food and Drug Administration clearance to sell its products there, and has set up a global headquarters in Boston, Massachusetts, to drive the expansion. Apart from selling to defence forces, the company has also launched haemostatic products for the cardiovascular and dental segments. “We have also come up with a kit for the automotive segment and are in talks with cab aggregators and vehicle manufacturers to include it with their offerings,” he says.
Top Stories
More FromIdeas
Cosmic Birla Group Portfolio Bears the Hallmark of Excellence and Innovation
The group’s portfolio of products spans cold-rolled formed sections, engineering items, railway parts and products in sectors like electrical transmission and defence.
The power of technology in modern HR payroll services
A Gartner survey found that less than one-third of the workforce express complete contentment with their work experiences.
Holani Group Launches ₹ 400 Crores SME Focused Fund
The fund has now been duly registered under SEBI as Category I AIF – Venture Capital Fund.
The visionary biotech entrepreneur: Arun Asaithambi’s journey from PhD to NASDAQ
The company’s remarkable journey included an IPO in 2020, raising over $100 million in total funding.
More FromIdeas
Cosmic Birla Group Portfolio Bears the Hallmark of Excellence and Innovation
The group’s portfolio of products spans cold-rolled formed sections, engineering items, railway parts and products in sectors like electrical transmission and defence.
The power of technology in modern HR payroll services
A Gartner survey found that less than one-third of the workforce express complete contentment with their work experiences.
Holani Group Launches ₹ 400 Crores SME Focused Fund
The fund has now been duly registered under SEBI as Category I AIF – Venture Capital Fund.
The visionary biotech entrepreneur: Arun Asaithambi’s journey from PhD to NASDAQ
The company’s remarkable journey included an IPO in 2020, raising over $100 million in total funding.
Leave a Comment
Your email address will not be published. Required field are marked*